William Blair Starts Ocular Therapeutix (OCUL) at Outperform, 'we believe Axpaxli has the potential to show best-in-class efficacy and durability'
Tweet Send to a Friend
(Updated - April 8, 2025 7:59 AM EDT)
William Blair analyst Lachlan Hanbury-Brown initiates coverage on Ocular Therapeutix (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
William Blair analyst Lachlan Hanbury-Brown initiates coverage on Ocular Therapeutix (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
